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A B S T R A C T
Background: Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 kg/m2) in-
dividuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD
in a population cohort of relatively young asymptomatic individuals who participated in a voluntary routine
health promotion evaluation in Brazil.
Methods: We analyzed data in our population collected from 2004 to 2016. Medical and demographic history,
anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess
for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders
identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at
follow-up.
Results: The prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years
(range 0.5–9.9 years), lean individuals had 74% (HR: 1.74 (1.39–2.18)) and 67% (1.67 (1.29–2.15)) greater risk
of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98
(2.10–4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of
developing elevated glucose (HR: 1.37 (1.07–1.75)) and atherogenic dyslipidemia (1.46 (1.05–2.01)) compared
to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP,
elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully
adjusted models.
Conclusion: Lean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate
preventive measures should be considered in lean individuals who present with NAFLD.
1. Background
Non-alcoholic fatty liver disease (NAFLD), defined by hepatic accu-
mulation of lipids among individuals without heavy alcohol consump-
tion, is a common metabolic disorder with a global prevalence of about
24% [1,2]. NAFLD is associated with adverse cardiovascular events
(including myocardial infarction, stroke, coronary revascularization),
atherosclerotic disease, cardiomyopathy, and cardiac arrhythmias [3,4].
The prevalence, incidence, and mortality from NAFLD continues to rise,
largely driven by progressively increasing obesity, metabolic syndromes,
and diabetes mellitus rates [5]. Analysis of the National Health and
Nutrition Examination Survey shows that the prevalence of NAFLD
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among normal weight (body mass indices [BMI]18.5 kg/m2 – 24.9
kg/m2) individuals is about 7–8% and increases with weight in a linear
fashion such that the prevalence of NAFLD is over 4 times greater among
those with BMI 35 kg/m2 [6].
Emerging data suggest that lean NAFLD (BMI<25 kg/m2) poses a
distinct clinical phenotype, one that is characterized by lower levels of
metabolic abnormalities such as insulin resistance and metabolic syn-
drome compared to non-lean individuals with NAFLD. In addition, lean
NAFLD is associated with the presence of genetic polymorphisms such as
the rs738409 variant of the phospholipase domain-containing protein 3
(PNPLA3) gene, which in turn is associated with a higher rate of hepatic
fibrosis [7]. However, recent studies have suggested that lean NAFLD
may not follow a benign course. Studies on mortality from lean NAFLD
are scarce, but suggest that lean NAFLD has similar or greater mortality
risk compared to non-lean NAFLD [8,9]. Considering the risks, there is
renewed interest in understanding the epidemiology and metabolic
consequences associated with the lean NAFLD phenotype.
Studies assessing cardiometabolic disease in lean NAFLD are limited.
Most of these are cross-sectional studies, and several are conducted in
symptomatic populations or those with elevated liver enzymes. Only a
few studies have focused on asymptomatic populations and even fewer
have examined the longitudinal cardiometabolic consequences of lean
NAFLD. Since cardiovascular disease (CVD) is the most common cause of
mortality among persons with NAFLD, it is paramount to assess these
intermediates which may give insights as to the mechanisms of mortality
and elucidate prevention targets in persons with NAFLD.
In this study, we seek to determine the cardiometabolic consequences
of lean NAFLD in a relatively young, asymptomatic population.
2. Methods
2.1. Study design
We analyzed data from a routine health promotion evaluation that
occurred at the Preventive Medicine Center of the Hospital Israelita Al-
bert Einstein in S~ao Paulo, Brazil from 2004 to 2016. Participants took
part in this exercise voluntarily and had multiple visits. At each visit,
participants filled out questionnaires on demographics, lifestyle
including smoking history and physical activity, assessed using the short
form of the international physical activity questionnaire (IPAQ), and
medical history including medication use. Anthropometric measures
including weight, height and abdominal circumference were also ob-
tained. Fasting blood samples were also obtained for lipid profile, hepatic
enzyme levels, blood glucose and high sensitivity C-reactive protein
(HsCRP). Other details of the study methodology have been published
elsewhere [10]. Analyses were restricted to participants with complete
data at baseline visit and a follow-up visit that was at least 6 months after
the baseline visit. The study was approved by the institutional review
board of the local institution.
2.2. Exposure assessment
All participants had ultrasonography to assess for the presence of fatty
liver. This was done after a 6 h fast using a Siemens ACUSONXP-10 de-
vice (Siemens AG, Mountain View, California). The images were read by
board certified radiologists who were unaware of the clinical or labora-
tory data of the participants. Fatty liver was assessed according to con-
ventional methods, based on the presence of increased hepatic
echogenicity making it distinguishable from the renal parenchyma of the
liver [11]. We defined NAFLD as fatty liver in individuals whose alcohol
use disorders identification test (AUDIT) score was less than 8. The
presence of an AUDIT score greater than 8 is associated with habitual
harmful alcohol drinking [12]. Body mass index (BMI) was calculated as
the weight in kg divided by the square of the height in meters (expressed
as kg/m2). Based on their BMI, participants were categorized as lean
(BMI 18.5–24.9 kg/m2) or non-lean (BMI 25 kg/m2 and above).
2.3. Outcome assessment
The main outcomes studied were cardiometabolic disorders such as
elevated blood pressure (BP), elevated glucose, atherogenic dyslipidemia
(defined as a combination of elevated triglycerides and low HDL
cholesterol) and elevated HsCRP. BP was obtained as a mean of three
resting measures, the first of which was obtained after a 5-min rest and in
accordance with the American Heart Association guidelines [13].
Plasma lipid, glucose, gamma glutamyl transferase (GGT), liver
transaminases (alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), and alkaline phosphatase levels were measured by
standardized automated laboratory tests using a VITROS platform
(Johnson & Johnson Clinical Diagnostics, New Brunswick, New Jersey).
Total cholesterol was measured by an enzymatic colorimetric method,
HDL-cholesterol was measured by a precipitation method while LDL-
cholesterol was calculated using the Friedewald formula (for triglycer-
ide levels less than 400 mg/dl). High-sensitivity C-reactive protein
(HsCRP) levels were determined by immunonephelometry (Dade-Behr-
ing GmbH, Mannheim, Germany). All laboratory testing was performed
at the Central Laboratory of the Hospital Israelita Albert Einstein.
Elevated BP was defined as a systolic BP of 130 mmHg or more, a
diastolic BP of 80 mmHg or more, the use of medications to treat hy-
pertension, or a self-reported history of hypertension. Considering that
some society guidelines such as the European society of cardiology/Eu-
ropean Society of Hypertension define hypertension as systolic BP  140
mmHg or diastolic BP 90mmHg, we also created an alternately defined
elevated blood pressure. This alternately defined elevated BP was char-
acterized as a systolic BP  140 mmHg or diastolic BP  90 mmHg, the
use of medications to treat hypertension, or a self-reported history of
hypertension. Elevated blood glucose was defined as a fasting blood
glucose above 100 mg/dl, a history of diabetes, or use of glucose
lowering medication. Atherogenic dyslipidemia (AD) was defined as a
combination of elevated triglycerides (>150 mg/dl) and low HDL-
cholesterol levels (<40 mg/dl for men and <50 mg/dl for women).
Finally, the presence of low-grade inflammation was determined if
HsCRP levels were >2.0 mg/L [14].
2.4. Statistical analysis
We excluded participants without complete data on variables of in-
terest. We also excluded participants with BMI less than 18.5 kg/m2, and
those with AUDIT scores 8 and those with follow-up less than 6 months
leaving a sample size of 9137 participants (see Fig. 1).
Participants were then categorized into 4 groups based on their BMI
and NAFLD status – Lean, without NAFLD; lean NAFLD; non-lean without
NAFLD; non-lean with NAFLD.
All collected data were assessed for normality. Means with standard
deviations (SD) were used to describe normally distributed continuous
variables, while medians with interquartile ranges (IQR) were computed
for non-normally distributed continuous variables. The analysis of
Fig. 1. Participant selection into the study.
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variance (ANOVA) was used to compare means across BMI-NAFLD
groups while the Kruskal-Wallis test was employed for comparing me-
dians across groups. For categorical variables, the frequencies (%) were
computed across the BMI-NAFLD groups and compared using chi-square
test.
We analyzed the incidence of the cardiometabolic disorders and
elevated HsCRP defined as the number of new cases in the population at
risk per person-year (PY). Next, we used the Cox proportional hazards
model to calculate hazard ratios (HR) and 95% confidence intervals (95%
CI) for the relationship between NAFLD groups and each of the afore-
mentioned cardiometabolic disorders. We compared lean NAFLD to the
each of the other BMI-NAFLD groups. From the data, we created three
models: the first was a univariate analysis, the second was adjusted for
age, sex, cigarette smoking, physical activity level, abdominal circum-
ference, and blood glucose (except for elevated blood glucose analysis).
The full model additionally adjusted for lipids – LDL-cholesterol, HDL-
cholesterol, triglycerides and total cholesterol (except in the AD anal-
ysis), use of lipid lowering therapy, and for liver enzymes gamma glu-
tamyl transferase (GGT), aspartate transaminase (AST), alanine
transaminase (ALT) and alkaline phosphatase (ALP). All incidence and
hazard ratio analysis excluded persons who had the outcome at baseline.
For instance, where elevated BP was the outcome, persons with elevated
BP at baseline were excluded but those with other cardiometabolic out-
comes (elevated glucose, HsCRP>2 or AD) were not excluded if they did
not have elevated BP at baseline. All statistical analysis was carried out
on Stata software version 16.
3. Results
3.1. General characteristics
The final study sample size of 9137 participants had a median follow-
up period of 2.4 years (IQR:1.6–4.0 years, range 0.5–9.9 years). At
baseline, the prevalence of lean NAFLD was 3.8%. The mean age of
participants was 42 years, and 75% were male. Lean NAFLD individuals
were older and more likely to be males compared to lean and non-lean
groups without NALFD. Waist circumference was larger among lean
NAFLD compared to lean without NAFLD. The prevalence of cigarette
smoking at baseline was generally low. Details on the baseline charac-
teristics can be found in Table 1.
3.2. Lean NAFLD and the relationship with cardiometabolic disorders
3.2.1. Elevated blood pressure
The incidence of elevated BP was 16 per 100PY in the entire popu-
lation, rising to 22 per 100PY and 26 per 100PY among lean NAFLD and
non-lean NAFLD. The incidence was lower (10 per 100PY) among lean
individuals without NAFLD. Details are shown in Fig. 2. In multivariate
analysis, the risk of elevated BP was 74% greater among lean NAFLD
compared to lean without NAFLD (HR 1.74 [95% CI:1.39–2.18]). There
was no statistically significant difference in the risk of elevated BP be-
tween lean NAFLD and non-lean individuals without NAFLD (HR:1.02
[95% CI:0.82–1.23]) and between lean NAFLD and non-lean individuals
with NAFLD (HR: 1.08 [95% CI: 0.85–1.36]). Details can be found in
Table 2.
When the definition of elevated blood pressure was modified to in-
crease the BP threshold 140 mmHg or diastolic BP  90 mmHg the
incidence of elevated BP was much lower overall (4.3 per 100PY),
however, the results of univariate and multivariate analysis comparing
Lean NAFLD to other BMI-NAFLD groups were similar. See Supplemen-
tary Tables S1 and S2 for details.
3.2.2. Elevated blood glucose
As shown in Fig. 2, the incidence of elevated blood glucose was 7.6
per 100PY in the entire population. The highest incidence was among
non-lean individuals with NAFLD (12.7 per 100PY), followed by lean
NAFLD individuals (9.3 per 100PY). Lean individuals without NAFLD
had the lowest incidence (4.0 per 100PY). In multivariate analysis, lean
NAFLD had 1.8 and 1.4 times the risk of elevated blood glucose compared
to lean, no NAFLD and non-lean no NAFLD respectively (HRs: 1.67 [95%
Table 1
Comparisons of demographic and metabolic characteristics of participants in Lean NAFLD compared to other groups at baseline among participants with follow-up data.
N ALL Lean, No NAFLD Lean NAFLD Non-Lean, no NAFLD Non-Lean, NAFLD P value
9137 3372 349 2880 2536
Mean Age (years, SD) 42 (9) 40 (8) 44 (9) 42 (9) 45 (8) <0.001
Sex (F %) 24.9 45.2 12.0 17.8 7.9 <0.001
Mean BMI (kg/m2, SD) 26.2 (4.0) 22.6 (1.6) 23.7 (1.1) 27.5 (2.3) 29.8 (3.7) <0.001
Mean abdominal circumference (cm, SD) 91.5 (12.4) 81.0 (8.0) 88.0 (6.2) 94.6 (8.1) 102.6 (10.2) <0.001
Mean SBP mmHg (SD) 117 (13) 111 (11) 118 (11) 119 (12) 124 (13) <0.001
Mean DBP mmHg (SD) 76 (8) 72 (7) 77 (7) 77 (7) 81 (8) <0.001
Mean Glucose (mg/dl, SD) 88.1 (13.7) 84.0 (9.4) 91.4 (18.5) 87.3 (9.5) 94.1 (18.7) <0.001
Smoker (%) 7.7 6.5 6.3 8.7 8.5 0.003
Minimally active or sedentary (%) 59.7 55.5 61.0 57.3 67.9 <0.001
Median total cholesterol (mg/dl, IQR) 195 (172–220) 188 (167–211) 199 (172–224) 197 (175–222) 202 (178–227) <0.001
Median LDL-c (mg/dl, IQR) 120
(100–144)
113 (93–135) 124 (101–144) 124 (104–148) 127 (105–150) <0.001
Median HDL-c (mg/dl, IQR) 47 (39–56) 53 (45–63) 45 (39–52) 46 (39–54) 41 (36–48) <0.001
Median triglycerides (mg/dl, IQR) 110 (79–157) 88 (66–119) 128 (93–186) 108 (80–149) 152 (111–205) <0.001
Median GGT (mg/dl, IQR) 27 (19–39) 21 (16–29) 31 (23–44) 27 (20–38) 36 (27–50) <0.001
Median Alkaline Phosphate (mg/dl, IQR) 63 (53–74) 60 (51–70) 64 (55–75) 64 (54–74) 67 (57–78) <0.001
Median Aspartate Aminotransferase (mg/dl, IQR) 27 (23–33) 25 (21–30) 29 (25–35) 27 (23–32) 31 (26–37) <0.001
Median Alanine Aminotransferase (mg/dl, IQR) 36 (27–47) 29 (23–37) 40 (33–54) 35 (28–45) 46 (36–61) <0.001
Median HsCRP (mg/dl, IQR) 1.2 (0.6–2.5) 0.8 (0.4–1.8) 1.0 (0.5–1.9) 1.2 (0.6–2.4) 1.8 (1.0–3.3) <0.001
Elevated BP (%) 54.4 32.8 58.2 59.3 76.9 <0.001
Elevated Glucose (%) 14.2 5.9 20.1 11.4 27.6 <0.001
Atherogenic Dyslipidemia (%) 14.8 4.4 20.3 12.9 30.2 <0.001
HsCRP2 (%) 30.9 22.4 23.1 30.2 44.1 <0.001
Use of Antihypertensive Medication (%) 11.0 3.8 8.9 10.0 22.0 <0.001
Use of Lipid lowering medication 9.9 5.1 10.9 1.7 15.1 <0.001
Glucose lowering medication 2.8 0.9 5.7 1.9 5.8 <0.001
Atherogenic Dyslipidemia: Defined as a combination of elevated triglycerides (150 mg/dl) AND low HDL-c (<40 mg/dl in men or <50 mg/dl in women).
LDL-c, low density lipoprotein cholesterol; HDL-c high density lipoprotein cholesterol; SD, standard deviation; IQR, interquartile range.
SBP systolic blood pressure, DBP diastolic blood pressure.
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CI:1.29–2.15] and HR:1.37 [95%CI:1.07–1.75]). Although the risk of
elevated glucose was lower among lean NAFLD compared to non-lean
NALFD on univariate analysis, the statistical significance was lost after
adjusting for possible confounders. Details can be found in Table 2.
3.2.3. Atherogenic dyslipidemia
The incidence of atherogenic dyslipidemia (defined here as elevated
triglycerides and low HDL) was 4.2 per 100PY in the entire population.
Persons without NAFLD had the lowest incidence (lean, no NAFLD 1.5
per 100PY and non-lean no NAFLD was 3.8 per 100PY). The incidence
was highest among non-lean individuals with NAFLD (8.1 per 100PY),
while lean NAFLD had an incidence of 5.5 per 100PY. In multivariate
analysis, lean NAFLD individuals were 3 times as likely to develop AD
compared to lean individuals without NAFLD (HR: 2.98 [95%CI:
2.10–4.24]). They were also 1.5 times as likely to develop AD compared
to non-lean individuals without NAFLD (HR: 1.46 [95%CI:1.05–2.01]).
Similar to the findings with elevated blood glucose, lean NAFLD,
compared to non-lean individuals with NAFLD, had a significantly
reduced risk of atherogenic dyslipidemia. However, the statistical sig-
nificance was lost after adjusting for potential confounders. See Fig. 2
and Table 2.
Fig. 2. The incidence of cardiometabolic abnormalities (per 100 person-years) across BMI-NAFLD groups.
Table 2
Hazard ratios for the longitudinal relationship between baseline NAFLD and new-onset cardiometabolic disorders.
Outcome Variable Models Lean NAFLD Vs. Lean, No NAFLD Lean NAFLD Vs. Non-Lean, No NAFLD Lean NAFLD Vs. Non-lean, NAFLD
Elevated Blood Pressurea
N ¼ 4436
Univariate 2.41 (1.94–3.00) 1.02 (0.82–1.26) 0.97 (0.70–1.08)
Minimally Adjustede 1.79 (1.43–2.24) 1.03 (0.83–1.29) 1.05 (0.83–1.33)
Fully Adjustedf 1.74 (1.39–2.18) 1.02 (0.82–1.23) 1.08 (0.85–1.36)
Elevated Blood Glucoseb
N ¼ 8113
Univariate 2.36 (1.85–3.02) 1.36 (1.07–1.73) 0.74 (0.59–0.93)
Minimally Adjusted 1.83 (1.42–2.35) 1.41 (1.10–1.79) 0.92 (0.72–1.12)
Fully Adjusted 1.67 (1.29–2.15) 1.37 (1.07–1.75) 0.96 (0.75–1.23)
HsCRP > 2c
N ¼ 6648
Univariate 1.15 (0.90–1.46) 0.86 (0.67–1.10) 0.72 (0.56–0.92)
Minimally Adjusted 1.17 (0.91–1.50) 0.98 (0.77–1.26) 0.89 (0.69–1.16)
Fully Adjusted 1.09 (0.84–1.41) 0.93 (0.73–1.02) 0.89 (0.69–1.15)
Atherogenic Dyslipidemiad
N ¼ 8058
Univariate 3.85 (2.73–5.42) 1.49 (1.09–2.04) 0.70 (0.52–0.95)
Minimally Adjusted 3.26 (2.30–4.63) 1.55 (1.12–2.14) 0.85 (0.62–1.18)
Fully Adjusted 2.98 (2.10–4.24) 1.46 (1.05–2.01) 0.86 (0.63–1.19)
Lean ¼ BMI 18.5 kg/m2 to <25 kg/m2. Non-lean ¼ BMI25kg/m2. NAFLD: Non-alcoholic Fatty Liver Disease.
Ns are sample sizes after excluding participants with the outcome at baseline.
a Persons with elevated blood pressure at baseline were excluded from the analyses.
b Persons with elevated blood glucose at baseline were excluded from the analyses.
c Persons with HSCRP >2 at baseline were excluded from the analyses.
d Persons with atherogenic dyslipidemia at baseline were excluded from the analyses.
e Minimally adjusted models were adjusted for age, sex, physical activity, smoking status, and abdominal circumference.
f Fully adjusted models had covariates as in minimally adjusted model plus lipids (total cholesterol, LDL-c, HDL-c, triglycerides except when AD [atherogenic dys-
lipidemia] was modeled as outcome variable), liver enzymes (GGT, Alkaline Phosphatase, Aspartate transaminase, Alanine transaminase), elevated blood glucose
(except when elevated blood glucose was modeled as outcome variable), elevated blood pressure (except when elevated blood pressure was modeled as the outcome
variable) and the use of cholesterol lowering medication for all 4 outcome variables.
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3.2.4. Elevated HsCRP
Lean persons with and without NAFLD had roughly similar incidence
of elevated HsCRP (9.1 and 8.1 per 100PY). This was lower than the
incidence in non-lean individuals with (12.9 per 100PY) and without
NAFLD (10.7 per 100PY). Details can be found in Fig. 2. There was no
statistically significant difference in the risk of elevated HsCRP between
lean NAFLD and lean, no NAFLD, and between lean NAFLD and non-lean
without NAFLD. Lean NAFLD had significantly reduced risk of elevated
HsCRP compared to non-lean individuals with NAFLD in univariate
analysis only. The statistical significance was lost after adjusting for
potential confounders (Table 2).
4. Discussion
In this longitudinal study of asymptomatic individuals, there was
elevated cardiometabolic (elevated BP, atherogenic dyslipidemia and
elevated glucose) risk among lean individuals with NAFLD compared to
lean individuals without NAFLD and to a lesser extent non-lean (over-
weight and obese) individuals without NAFLD. Lean and non-lean in-
dividuals with NAFLD had similar cardiometabolic risk. These results
suggest that lean NAFLD has significant cardiometabolic consequences
and raising further questions about its proposed benign course.
Several studies have demonstrated an association between lean
NAFLD and BP. In a previous cross-sectional study of working class
Brazilians, prevalent NAFLD was associated with BP in the hypertension
range among individuals with BMI <30 kg/m2 [10]. Other studies have
validated the cross-sectional association between elevated BP and NAFLD
in lean individuals [15,16]. However, only a few studies have investi-
gated the risk of incident hypertension or elevated BP among lean
NAFLD. One such study from Sri Lanka which compared 50 individuals
with lean NAFLD at baseline with 260 non-lean NAFLD and 544 in-
dividuals without NAFLD showed no statistically significant difference in
the incidence of hypertension over a seven-year period among groups
[17]. By contrast, the present study, which has a larger sample size and
greater number of lean NAFLD participants, showed significant risk of
incident elevated BP among lean NAFLD compared to lean and non-lean
groups without NAFLD. The reason for the dissimilarity in findings re-
mains unclear. However, in addition to the present study having a larger
population of individuals with lean NAFLD, elevated BP was defined
using less strict criteria and participants were considerably younger (42
years vs 54 years). Changing the definition of elevated BP to one with
higher systolic and diastolic BP thresholds did not significantly alter the
results of regression analysis.
Atherogenic dyslipidemia, defined as elevated levels of triglycerides,
and small-dense LDL with low levels of HDL-cholesterol is a central
feature in the development of diabetes and is a marker of both metabolic
syndrome and insulin resistance [18]. AD is associated with increased
risk of coronary artery disease [19]. Numerous studies have shown a
relationship between lean NAFLD andmeasures of insulin resistance such
as HOMA-IR [20–22]. While several studies have demonstrated
cross-sectional relationships between lean NAFLD and lipids in general,
to our knowledge, the present study is the first to assess the temporality
of atherogenic dyslipidemia in lean NAFLD. The increased risk of AD in
lean NAFLD over those who were non-lean but without NAFLD suggests
that NAFLD may be a greater marker of atherogenicity than BMI and
lends credence to the theory of insulin resistance as one of the drivers of
lean NAFLD [23].
Low-grade inflammation, oftenmeasured by an elevation in HsCRP, is
associated with cardiovascular disease onset and is regarded as a marker
of subclinical atherosclerosis [14]. NAFLD in general has been linked to
increase in the risk of low-grade inflammation [24–26]. We found no
studies specifically examining relationships between lean NAFLD and
low-grade inflammation. In the present study, there was no difference in
the risk of elevated HS-CRP between lean NAFLD and lean individuals
without NAFLD, and between lean NAFLD and non-lean individuals
without or with NAFLD.
At the heart of the definition of lean NAFLD is a BMI measure of
leanness. Our study shows that among lean individuals, those with
NAFLD had higher waist circumference compared to those without
NAFLD. It is unclear if a shift in the definition of lean NAFLD from a BMI-
based measure to waist circumference-based definition will yield
different results. Several large epidemiologic studies indicate that waist
circumference is a better predictor of CVD and all-cause mortality [27,
28]. This suggests that a waist circumference-based definition of lean
NAFLD may be more predictive of cardiometabolic outcomes than the
current definition. This needs to be explored further however, it is
beyond the scope of the present study.
Diabetes and hypertension have been linked with all-cause mortality
in lean NAFLD [17,29,30]. At least one study suggests that diabetes may
be a predictor of cardiovascular mortality in lean NAFLD and a recent
study in individuals with biopsy proven NAFLD showed that hyperten-
sion was an independent risk of mortality [31]. Thus, cardiometabolic
disorders in lean NAFLD have significant prognostic implications. The
findings from this study highlight the importance of lean NAFLD in the
development of cardiometabolic disorders and adds mechanistic insight
to the elevated CVD risk associated with lean NAFLD. The present study,
which shows that lean NAFLD poses greater cardiometabolic risk than
non NAFLD groups regardless of BMI, but exhibits similar risk of
low-grade inflammation compared to non NAFLD groups, suggests that
lean NAFLD is phenotypically distinct from the other BMI-NAFLD groups.
The findings of this study should spur providers whomanage lean NAFLD
patients to monitor closely for the development of cardiometabolic dis-
orders. There is obviously more work needed to fully understand the
relationships between NAFLD in lean/non-obese adults and car-
diometabolic risk and how this risk translates to the occurrence of CVD
later in life. For instance, there is no data measuring the incidence or
progression of coronary artery calcification, a surrogate marker of
atherosclerosis plaque burden and an independent marker of CVD events,
in lean NAFLD.
The main strengths of this study include its longitudinal nature that
has allowed for assessment of the temporal relationship between lean
NAFLD and cardiometabolic disorders. The large sample size allows for a
more robust comparison of multiple subgroups. In addition, the present
study adjusted for several important covariates in regression analyses
including central obesity (waist circumference) and the use of lipid
lowering medication. It is one of only a few population-level studies to
longitudinally assess cardiometabolic risk associated with lean NAFLD in
an otherwise asymptomatic population.
Our study is limited by its retrospective design in which data on
several variables were not collected. Hepatic steatosis was determined by
ultrasound which has limited sensitivity for the diagnosis of steatosis
[32]. Nonetheless, ultrasound estimation is an affordable and safe way to
diagnose liver fat and is commonly used in clinical practice. Beyond BMI,
waist circumference and hepatic steatosis, there were no other measures
of adiposity collected in this study. Thus, we are unable to account for
these other measures in our definition of leanness or in our multivariate
analyses. In most clinical and public health settings, BMI and waist
circumference are the most often assessed measures of adiposity used in
clinical and public health/policy decision making. Thus, we deem our
findings are of clinical and public health relevance regardless of this
limitation. The participants in our study were young (average age was 42
years), largely male (75%) and Brazilian thus our findings cannot be
generalized to older adults, largely female populations, or other ethnic-
ities. Finally, approximately 65% of participants who did not have a
follow-up were excluded from the study which may have introduced
selection bias.
5. Conclusions
The risk of cardiometabolic disorders among lean persons with
NAFLD is greater than individuals without NAFLD regardless of their BMI
status. This suggests that lean NAFLD is not a metabolically benign
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condition. Health care providers who treat lean NAFLD patients should
strongly consider further cardiovascular disease risk stratification,
appropriate preventative measures and monitoring even if their patients
are asymptomatic. Future investigative efforts should focus on the
mechanisms driving increased cardiometabolic risk and how this trans-
lates to hard CVD outcomes in lean individuals with NAFLD.
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